Deubiquitinases as Prognostic Biomarker and Potential Drug Target for Gynecological Cancers
Abstract
Background
To
develop
Deubiquitinase-Associated
Signatures
(DAS)
to
predict
the
prognosis
of
gynecological
cancer
patients.
Methods
Using
a
cox-lasso
regression
model,
we
have
developed
Deubiquitinase-associated
signatures
for
Cervical,
Ovarian,
and
Uterine
cancers.
Developed
DAS
were
validated
in
TCGA
GEO
datasets.
Survival
analysis
was
carried
out
know
effect
factors
like
menopausal
stage
grade
on
DAS.
The
survival
prediction
accuracy
analyzed
using
ROC
curves.
Immune
infiltration
scores
22
immune
subtypes
explored
CIBERSORT
package
risk
groups
classified
by
Further,
target
unfavorable
deubiquitinases
(DUBs),
compounds
identified
CMap
database.
Results
Three
types.
able
classify
patients
into
two
is
an
independent
predictor
irrespective
tumor
stage.
DAS,
along
with
clinical
features,
improves
predictions.
has
shown
that
cell
associated
divided
CMap,
52
DUBs.
Conclusion
good
survival,
targeting
DUBs
can
decrease
progression
Research Square (Research Square), Год журнала: 2025, Номер unknown
Опубликована: Май 7, 2025
Язык: Английский